Self-limited neonatal epilepsy

Self-limited neonatal epilepsy, formerly known as benign familial neonatal epilepsy (BFNE) or benign familial neonatal seizures (BFNS), is a rare genetic epilepsy syndrome characterized by seizures that begin in the first days to weeks of life in otherwise healthy newborns. The condition primarily affects the central nervous system. Seizures typically present between the second and seventh day of life and are often brief, consisting of tonic posturing, clonic movements, apneic episodes, and autonomic features such as changes in skin color or heart rate. Seizures may occur multiple times per day but characteristically resolve spontaneously, usually within weeks to months, hence the term 'self-limited.' The condition is most commonly caused by pathogenic variants in the KCNQ2 gene (chromosome 20q13.3) and less frequently in the KCNQ3 gene (chromosome 8q24). These genes encode voltage-gated potassium channel subunits (Kv7.2 and Kv7.3, respectively) that play a critical role in regulating neuronal excitability. Loss-of-function variants in these channels lead to increased neuronal firing and seizure susceptibility during the neonatal period. The prognosis is generally favorable. The majority of affected infants have normal neurodevelopmental outcomes, and seizures typically cease by 6 months of age without long-term treatment. However, approximately 10-15% of individuals may develop epilepsy later in life, most commonly in adolescence or adulthood. During the neonatal period, seizures may be treated with antiseizure medications such as phenobarbital or carbamazepine. Sodium channel blockers like carbamazepine and phenytoin have shown particular efficacy in some cases. Genetic counseling is recommended for affected families given the autosomal dominant inheritance pattern.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Self-limited neonatal epilepsy